13 news items
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune
Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
BMY
3 Jun 24
The most common adverse reaction(s) (incidence ≥30%) in:
LBCL are fever, cytokine release
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY
30 May 24
.
Adverse Reactions
The most common adverse reaction(s) (incidence ≥30
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
BMY
23 May 24
. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune- mediated
p9eq9dlvxw5qmu3rsdy0kr1pj sh5hvizds75fzyab9l
BMY
16 May 24
) for the safety analyses. With increased exposure to Sotyktu, the exposure-adjusted incidence rates
e4lxy2gwaar0qt61i2j
BMY
15 May 24
.
Adverse Reactions
The most common adverse reactions (incidence ≥ 30
xvg5r81eqmpxrj9j26hbxbusnoc90cjmrthg8cjms3yj18r6qyhdg
BMY
10 May 24
and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation
uo3xwpuvbp1w fjdm
BMY
26 Apr 24
OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic
omu6a86papylpykp9td6uex7cmwefk5tcsir8hmq7y5dxnehazrzz
BMY
TSVT
5 Apr 24
adverse reactions (incidence greater than or equal to 20%) include pyrexia, CRS, hypogammaglobulinemia, infections – pathogen unspecified
f6j8jbe1bcu7b0iu999izdpxct5
BMY
2 Apr 24
Hypertension was reported in 11.4% (63/554) of REBLOZYL-treated patients. Across clinical studies, the incidence of Grade 3 to 4
2z6e7w8rdvwhjg52k09ohymgfzpdaedxcmthmfhypps6q29n 4f1zd
BMY
25 Mar 24
from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF <50% in over 1500 patients, strengthening the safety profile
rkwsfylih186wbcfa7a5hfkib7hqtytc398tr97trcldd2oxxufyl1w aqjl
BMY
14 Mar 24
(incidence ≥ 30%) in:
LBCL are fever, cytokine
- Prev
- 1
- Next